Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Radius Health, Inc. RDUS
$10.08
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
23.00
-
week52low
4.97
-
Revenue
229973000
-
P/E TTM
-8
-
Beta
0.51647000
-
EPS
-1.53600000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 авг 2022 г. в 04:00
Описание компании
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 24 июн 2022 г. |
| B of A Securities | Neutral | Underperform | 08 июн 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| SVB Leerink | Market Perform | 23 мая 2022 г. | |
| Morgan Stanley | Underweight | Equal-Weight | 10 дек 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lisa Susan Vissers | D | 0 | 30000 | 15 авг 2022 г. |
| SANDERS MACHELLE | D | 0 | 10000 | 15 авг 2022 г. |
| SANDERS MACHELLE | D | 0 | 10000 | 15 авг 2022 г. |
| Hughes Owen | D | 0 | 32894 | 15 авг 2022 г. |
| Hughes Owen | D | 0 | 21650 | 15 авг 2022 г. |
| Shah Chhaya | D | 0 | 94645 | 15 авг 2022 г. |
| FRIEDMAN CATHY | D | 0 | 10000 | 15 авг 2022 г. |
| FRIEDMAN CATHY | D | 0 | 10000 | 15 авг 2022 г. |
| Murphy Sean | D | 0 | 10000 | 15 авг 2022 г. |
| Murphy Sean | D | 0 | 5500 | 15 авг 2022 г. |
Новостная лента
Dave & Busters, USA Truck See Activist Investor Action
Market Watch
15 июл 2022 г. в 17:30
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
Zacks Investment Research
08 июл 2022 г. в 13:13
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.